The serological response to Trichosporon sp. was examined by the immunoblot technique. Antibodies to a range of antigens (200 to 16 kilodaltons) were detectable in three patients with invasive Trichosporon beigelii or Blastoschizomyces capitatus infections and 10 uninfected controls. High levels of preexisting antibodies may contribute to the rarity of systemic infections.
Systemic infection with Trichosporon beigelii (formerly Trichosporon cutaneum) or Blastoschizomyces capitatus (formerly Trichosporon capitatum) is rare but increasingly recognized. Of the 25 cases reported, 13 have occurred in patients with acute leukemia (2, 5-7, 10, 17, 18, 21, 26) . Others were associated with multiple myeloma (7, 19) , aplastic anemia (15, 25) , renal transplantation (19) , chronic active hepatitis (9) , bronchial carcinoma (24) , endocarditis (1, 3, 13) , and intracapsular lens extraction (20) . T. beigelii caused 18, B. capitatus caused 6, and an unknown Trichosporon species caused 1 of these cases. Overall mortality was 78%. Such infection has not been associated with diseases characterized by impaired mononuclear cellmediated immunity, such as Hodgkin's disease, suggesting deficits in delayed hypersensitivity is not a major underlying susceptibility factor.
Trichosporon species are normal inhabitants of the soil, and T. beigelii may cause white piedra, a superficial infection of the hair shaft. Of 3,340 clinical yeast isolates at the Memorial Sloan-Kettering Cancer Center, New York, N.Y., only 13 (0.4%) were T. beigelii, compared with 2,289 (68.5%) Candida albicans (8) . Rivera and Cangir noted a recent increase in the frequency of T. beigelii from throat and urine cultures, but only one of their severely immunocompromised patients developed clinical disease (18) . When 353 severely immunocompromised patients at the Johns Hopkins Oncology Center, Baltimore, Md., were screened for Trichosporon species over a 37-month period, 13 patients (3.7%) had positive stool, skin, or urine cultures, but only 3 of them developed systemic disease (7) . It therefore appears that immunosuppressed patients colonized with Trichosporon species can often successfully resist the development of invasive disease. Antibody may have some protective value. The immunoblotting technique was used to analyze the serological response to Trichosporon species in 3 patients with systemic infections and 10 controls, 6 of whom were severely immunocompromised leukemic patients.
The two patients who died from systemic B. capitatus infections, as reported elsewhere (2), were undergoing induction chemotherapy for acute myeloblastic leukemia when B. capitatus was isolated from blood cultures. At autopsy, histological examination showed involvement of the spleen, esophagus, and kidneys of both patients. B. capitatus was cultured from the spleen and kidney of one patient and from the spleen, kidney, lung, and liver of the other. The third patient was a 60-year-old female undergoing cytotoxic chemotherapy for acute myeloid leukemia who developed fever unresponsive to antibiotics and a scattered erythematous macular rash. Blood cultures grew T. beigelii. The pyrexia resolved with amphotericin B which was discontinued after 300 mg due to deterioration of renal function. There was a concomitant resolution of her neutropenia. None of these patients was colonized by C. albicans. Four sera from each patient were examined in the same run so that any changes observed did not reflect changes in the analytical method, and the blots were repeated when possible. There was insufficient serum to prepare blots against B. capitatus and T. beigelii, and the latter was examined because it is a more common infection (8) .
Control sera were obtained from six other leukemic patients and four postoperative surgical patients treated for gram-negative septicemias. Concomitantly, all six leukemic patients had oral C. albicans infections, confirmed by culture, but none of them had systemic candidosis according to clinical, cultural, and serological criteria (14) . When screened, none of the leukemic or surgical controls grew B. capitatus or T. beigelii from oral and perineal swabs, nor did samples from the surgical patients grow C. albicans.
T. beigelii NCPF 3077 was grown on Sabouraud glucose agar at 30°C for 3 days, harvested, washed three times in distilled water, and disrupted in a Mickle homogenizer for 30 min. After being centrifuged at 12,000 x g for 10 min, the supernatant was assayed for protein by the method of Lowry et al. (12) . C. albicans NCTC 3153 was prepared similarly. Immunoblotting was performed as previously described (4, 14) . Briefly, 50 ,ug of T. beigelii or C. albicans was applied to a 10% slab gel, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed in a discontinuous buffer system (11) . A current (90 V, 350 mA) was applied for 1.5 h for transfer from gel to nitrocellulose membrane in a transblotting chamber (Bio-Rad Laboratories, Richmond, Calif.), essentially as described by Towbin et al. (23) , with as buffer 25 (Fig. 3) , despite the fact that none of them was colonized with T. beigelii but six were colonized with C. albicans. The presence of antibody to Trichosporon spp. may reflect prior exposure to this yeast. Unlike C. albicans, it is common in the environment but infrequently isolated from man (7, 8) . Alternatively, the presence of antibody may have been due to cross-reaction with some other organism. Recently, cross-reactivity was described between antibody to T. beigelii and another basidiomycetous yeast, Cryptococcus neoformans (15) . Whatever the origin of this preexisting antibody, it may be protective. Because it is present even in severely immunocompromised patients, it may be one of the reasons for the rarity of invasive Trichosporon infections compared with systemic candidosis. Unfortunately, it will also make serodiagnostic tests based on antibody detection for this infection difficult to develop.
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